Lyell immunopharma inc LYEL.US 總覽分析
LYEL 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
LYEL 近期報酬表現
-5.79%
Lyell immunopharma inc
1.99%
同產業平均
-0.64%
S&P500
與 LYEL 同產業的標的表現
- BCAX Bicara therapeutics inc價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
LYEL 公司資訊
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.